Carcinosarcoma — Trials

Carcinosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

77 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 22
Recruiting: 13
Ph III recruiting: 5
Growth YoY: —
Industry share: 5%
Top sponsor: Mayo Clinic
Termination share: 46.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06393751	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer	withdrawn	Phase 1 / Phase 2	0	National Cancer Institute (NCI)NIH	0	Jun 3, 2025	clinicaltrials
NCT03933761	Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy(PRECISE)	withdrawn	Phase 2	0	Australia New Zealand Gynaecological Oncology Group